ESMO 24: Investors Are Starting To Believe In BioNTech’s Cancer Drugs

 
• By Andrew McConaghie

The company’s investment in oncology is starting to pay off, with its PD-L1/VEGF inhibitor BNT324 generating particular interest at ESMO.

BioNTech Shutterstock
• Source: Shutterstock

More from ESMO

More from Conferences